Treatment to COVID-19 Based on Theory of Simultaneous Treatment to Lung and Large Intestine: a Preliminary Clinical Trial

XIA Xintian; WEN Minyong; ZHAN Shaofeng; CHEN Weitao; HE Jing

Suggestions

您当前的位置：

首页 >

文章列表页 >

Treatment to COVID-19 Based on Theory of Simultaneous Treatment to Lung and Large Intestine: a Preliminary Clinical Trial

Previous: Discussion on Characteristics of Diagnosis and Treatment of BAI Changchuan

Next: SI Guom in's Experience in Treatment of Vessel Impediment Based on Syndrome-differentiation of Qi and Blood

Treatment to COVID-19 Based on Theory of Simultaneous Treatment to Lung and Large Intestine: a Preliminary Clinical Trial
1.The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China
DOI：

扫描看全文

XIA Xintian, WEN Minyong, ZHAN Shaofeng, et al. Treatment to COVID-19 Based on Theory of Simultaneous Treatment to Lung and Large Intestine: a Preliminary Clinical Trial[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=39382472&Fpath=home&index=0
DOI：

XIA Xintian, WEN Minyong, ZHAN Shaofeng, et al. Treatment to COVID-19 Based on Theory of Simultaneous Treatment to Lung and Large Intestine: a Preliminary Clinical Trial[DB/OL].（2023-09-15）[2023-11-05].http://cccl-tcm.cacm.org.cn/thesisDetails?columnId=39382472&Fpath=home&index=0 DOI：

摘要

新型冠状病毒肺炎自从疫情暴发以来，已造成多个地区流行，目前尚缺乏有效的针对性治疗措施。面对重大疫情，广州中医药大学第一附属医院第一时间成立专家团队支援武汉，开展临床诊治。临证观察总结发现，武汉地区大部分患者同时存在肺部症状与胃肠症状。主要病因为天行时疫；病邪性质为湿热邪毒；病机特点为邪伏膜原，肺肠同病；运用“肺肠同治”理论开展临床辨证施治，获效尚佳。现将经验体会总结汇报，以期为中医药治疗新型冠状病毒肺炎提供新的思路。

Abstract

Since the outbreak of COVID-19, it has caused epidemic in many areas, and there are still no effective targeted treatment measures. In the face of a major epidemic, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine sets up an expert team to support Wuhan for clinical diagnosis and treatment. Clinical observation and summary has found that most patients in Wuhan have lung symptoms and gastrointestinal symptoms at the same time. The main disease is the natural epidemic. The nature of disease pathogen is damp, heat and toxin. The pathogenesis is characterized by pathogenic membrane, lung and intestine. Using the theory of "simultaneous treatment of lung and intestine" to carry out clinical syndrome differentiation and treatment can get satisfactory effect. The experience was summarized and reported so as to provide a new train of thought for the treatment of COVID-19 with traditional Chinese medicine.

关键词

新型冠状病毒感染肺炎肺肠同病肺肠同治

Keywords

COVID-19disease of both lung and large intestinesimultaneous treatment to lung and large intestine

references

王玉光, 齐文升, 马家驹, 等. 新型冠状病毒肺炎中医临床特征与辨证治疗初探[J]. 中医杂志, 2020, 61(4): 281-285.

LI Q, GUAN X, WU P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia[J]. N Engl J Med, 2020, 382(13): 1199-1207.

HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.

中华人民共和国国家卫生健康委员会卫生应急办公室. 截至2月14日24时新型冠状病毒感染的肺炎疫情最新情况[EB/OL]. (2020-02-14)[2020-02-15]. http://www.anshan.gov.cn/html/ASSZF/202102/0161334630986840.htmlhttp://www.anshan.gov.cn/html/ASSZF/202102/0161334630986840.html

新型冠状病毒感染的肺炎诊疗方案(试行第五版)[J]. 江苏中医药, 2020, 52(2): 95-96.

宋杲, 成梦群, 魏贤文. 新型冠状病毒(2019-nCoV)治疗药物体内外研究及药物研发进展[J]. 病毒学报, 2020, 36(2): 300-305.

庞文渊, 王乔羽, 赵志刚. 新型冠状病毒肺炎的药物治疗方案及研究进展[J]. 临床药物治疗杂志, 2020, 18(2): 24-29.

WANG X, LIU Z. Prevention and treatment of viral respiratory infections by traditional Chinese herbs[J]. Chin Med J(Engl), 2014, 127(7): 1344-1350.

刘敏, 王庆国. 中医药在防治传染性非典型肺炎中的贡献及反思[J]. 中国新药杂志, 2004(S1): 1209-1211.

WU F, ZHAO S, YU B, et al. A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020, 579(7798): 265-269.

ZHOU P, YANG X L, WANG X G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273.

LEUNG W K, TO K F, CHAN P K, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection[J]. Gastroenterology, 2003, 125(4): 1011-1017.

ZHANG J Z. Severe acute respiratory syndrome and its lesions in digestive system[J]. World J Gastroenterol, 2003, 9(6): 1135-1138.

CHEN N, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.

CHAN J F, YUAN S, KOK K H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523.

CHANG , LIN M, WEI L, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China[J]. JAMA, 2020, 323(11): 1092-1093.

KUBA K, IMAI Y, RAO S, et al. A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury[J]. Nat Med, 2005, 11(8): 875-879.

de LANG A, OSTERHAUS A D, HAAGMANS B L. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells[J]. Virology, 2006, 353(2): 474-481.

CHAN J F, KOK K H, ZHU Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated　from a patient with atypical pneumonia after visiting Wuhan[J]. Emerg Microbes Infect, 2020, 9(1): 221-236.

ZHOU P, YANG X L, WANG X G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin[J]. Bio Rxiv, 2020(22): 914952.

新华社杭州. 对传染病思想上永远不能松懈——与李兰娟院士面对面[EB/OL]. (1899-01-30)http://society.people.com.cn/n1/2020/0130/c1008-31565352.htmlhttp://society.people.com.cn/n1/2020/0130/c1008-31565352.html.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰